Daito announced that it will establish a joint venture with Meiji Seika Pharma and Development Bank of Japan to take over Kyorin Pharmaceutical's generic-drug business. The new company will be based in Toyama City and is scheduled to be established in December, after which it will proceed with the business transfer.
Daito announced that it will establish a joint venture with Meiji Seika Pharma and Development Bank of Japan to take over Kyorin Pharmaceutical's generic-drug business. All 3 parties will participate in establishing the new company.
The name of the new company has not been disclosed, but it is expected to become an organization responsible for transferring the generic-drug business and to take over the relevant business from Kyorin Pharmaceutical. The new structure is expected to be operated through cooperation among the 3 parties.
The new company will be based in Toyama City and is scheduled to be established in December. Details of the specific business plan and the scope of the transfer are expected to be announced at a later date.